Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study

Borgonovo, Fabio; Passerini, M Gambacorti; Piscaglia, Marco; Morena, Valentina; Giacomelli, Andrea; Oreni, Letizia; Dedivitiis, Gianfranco; Lupo, A; Falvella, S.; Cossu, Maria Vittoria; Capetti, Amedeo

doi:10.1016/j.jinf.2021.01.023

Cited by 6 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among two healthcare workers who were seropositive got infected, one had mild symptoms of cold, and vomiting who is a known asthmatic and allergy to dust (antibody was proportionately increased to double the value before infection), whereas the other one was asymptomatic who has past history of allergy to dust suggesting that antibody levels might prevent development of severe symptoms in contrast to seronegative person who developed symptoms. Our study had three vaccine breakthrough infection following two doses of vaccination after 6 months in comparison with Lumley et al and Borgonovo et al who showed that incidence of reinfection is significantly lower in healthcare workers with SARS-COV-2 anti-spike antibody [13,14]. Majority of the participants had sustained response of anti-spike (RBD) antibodies after 6 months of vaccination in comparison with a study by Ketas et al who monitored 45 healthy recipients of either Pfizer BNT162b2 or Moderna mRNA-1273 mRNA vaccines showed sustained antibody response to all anti-SARS-COV-2 RBD antibodies after 3 months of complete vaccination [15].…”

Section: Discussionsupporting

confidence: 55%

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

DODDAMANI²,

KISHANRAO³

et al. 2022

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: The objectives of this study were semi-quantitatively analyze SARS-COV-2 IgG antibodies following covishield vaccination in healthcare workers and to follow-up them for 6 months for persistence of antibodies and for getting infected with SARS-COV-2. Methods: This was a prospective cohort study which was conducted at tertiary care hospital, South India. The blood samples were collected after second dose of vaccine at 28 days, 60 days, and 120 days. The serum was subjected for detection of IgG antibodies against S1 RBD (Receptor binding domain) of the spike protein antigen by Euroimmun kit (PerkinElmer company, Germany) using ELISA. Results: Out of 30 healthcare workers, 28 (93.3%) were seropositive and 2 (6.7%) were seronegative. Out of two seronegative, one participant acquired SARS-COV-2 infection with severe symptoms. There was approximately 50% reduction in antibody levels in almost all seropositive individuals after 3 months of second dose. Even after 6 months, 25 (83.3%) were seropositive, 2 (6.7%) were seronegative, and 3 (10%) were borderline. When the IgG antibody ratio levels of 28 days following second dose of vaccination were compared with levels after 6 months, which showed, p value of 0.024 which is <0.05 implies statistically significant. Conclusion: Covishield vaccine induced good immune response in majority of the participants, the levels were sustainably positive until 6 months but decreasing pattern. The vaccine-induced antibodies prevented the severe symptoms among vaccine breakthrough infections.

show abstract

Section: Discussionsupporting

confidence: 55%

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

DODDAMANI²,

KISHANRAO³

et al. 2022

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Rates of reinfection can be considerable, with one Kenyan study finding that, within 6 months of a primary infection, reinfection among study participants occurred at rates of 21%, 5.7%, and 4.0% for NL63, OC43, and 229E, respectively (Kiyuka et al, 2018). Specific IgG and neutralizing antibodies have been detected in recovered COVID-19 patients for at least 5-8 months after infection, suggesting a prolonged humoral immune response and the potential for protection against reinfection and disease (Wajnberg et al, 2020;Borgonovo et al, 2021;Fotouhi et al, 2021;Chvatal-Medina et al, 2021;Gudbjartsson et al, 2020;Dan et al, 2021;Lumley et al, 2021). However, some studies have suggested that the intensity and longevity of the SARS-CoV-2 humoral responses correlate with disease severity, with IgG and neutralizing antibody titers declining more rapidly (within 1-4 months) (Ibarrondo et al, 2020;Lau et al, 2021;Long et al, 2020;Roltgen et al, 2020;Self et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract

et al. 2022

View full text Add to dashboard Cite

“…Antibodies against spike protein and / or nucleocapsid have been shown to be protective (21). In the study conducted by Borgonovo et al,itwas shown that IgG formed against spike protein continued for 7 months and symptomatic COVID-19 infection did not develop in these people (22). In another study by Zhang et al,itwas shown that B lymphocyte response developed in the rst 14 days after a single dose of CoronaVac vaccine, but T lymphocyte response developed after the second dose (23).…”

Section: Discussionmentioning

confidence: 99%

Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report

Binay

Karakeçili

Barkay

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: It is necessary to use an effective vaccine to end the COVID-19 pandemic.CoronaVac vaccine is used in our country and we aimed to examine the level of antibody development after theseconddose.Methods:This is a retrospective, cross-sectional research. The dataof the people, who applied to a university hospital between January and March 2021, were analyzed. Those who had SARS-CoV-2 IgG and IgMmeasurement in the previous two weeks before the CoronoVac vaccine, and those who were both found negative and who had SARS-CoV-2 IgG and IgM measurement after the seconddose of CoronaVac vaccine were included in the research. SARS-CoV-2 IgG/IgM were measured by VIDAS® (BioMérieux, Marcy-l'Etoile, France) device for the detection of spike protein specific IgG/IgM of SARS-CoV-2 in human serum with ELFA (Enzyme Linked Fluorescent Assay) technique.Results: 75 people were included in thisresearch. It was found that the individuals had SARS-CoV-2 IgG and IgM measurements between 14 and 21 days after the first dose of CoronaVac vaccine.It was observed that 12% (n = 9) of the cases had a history of COVID-19.The rate of positivity for SARS CoV-2 IgG level after vaccination was 100%.Conclusions: It can be said that two doses of CoronaVac vaccine create an effective humoral immunity.

show abstract

Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study

Cited by 6 publications

References 7 publications

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract

Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report

Contact Info

Product

Resources

About